M.D., Ph.D., Co-Founder and Chief Science Officer, Genomenon
Biography
Dr. Kiel oversees Genomenon's scientific direction and product development. In 2014, Mark founded the company and created the Mastermind Genomic Search Engine, which connects doctors with evidence in the literature to help diagnose patients with genetic diseases and cancer. Prior to starting Genomenon, Mark completed his residency in Clinical Pathology in 2014 at the University of Michigan. While at Michigan, he completed a fellowship in Molecular Diagnostics and devised the informatics framework for clinical next-generation sequencing in the Molecular Diagnostics Laboratory. During his doctoral studies, he made ground-breaking contributions to the study of hematopoietic stem cells, for which he was awarded the Weintraub International Graduate Student Award and the ProQuest Distinguished Dissertation Award. While a post-doctoral researcher, he made significant contributions to the field of Hematopathology, including genomic profiling of lymphoid malignancies, for which he was awarded the Benjamin Castleman Award.
AI and Data Science Showcase:
Genomenon
Genomenon, home of the Mastermind Genomic Search Engine, connects patient DNA with the billions of dollars spent on research to help doctors diagnose and cure cancer patients and babies with rare diseases.
Curating The Entire Human Genome At Scale
Understanding the genomic drivers of disease is essential for precision medicine, but manual curation cannot handle the massive amount of information being generated by NGS. Dr. Kiel will demonstrate the technology to curate the entire human genome using a combination of ML and manual approaches.
Session Abstract – PMWC 2020 Silicon Valley
Track 7 - January 22 9.00 A.M.-3.45 P.M.,Track 6 - January 23 11.15 A.M.-11.30 A.M.,Track 2 - January 24 11.15 A.M.-4.00 P.M.
The PMWC 2020 AI Company Showcase will provide a 15-minute time slot for selected AI companies to present their latest technologies to an audience of leading investors, potential clients, and partners. We will hear from companies building technologies that expedite the pre-clinical and clinical drug discovery and development process, accelerate patient diagnosis and treatment, or develop scalable systems framework to make AI and deep/machine learning a reality.
